Cameron Turtle compensation by year
Spyre Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $272,850 | $625,000 | $665,000 |
| Bonus | $141,000 | $0 | $0 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $15,500,492 | $5,914,353 | $5,552,886 |
| Non-equity incentive | $0 | $412,500 | $475,475 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $5,203 | $8,333 | $14,000 |
| Total | $15,919,545 | $6,960,186 | $6,707,361 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Spyre Therapeutics, Inc. DEF 14A filed April 10, 2026, accession 0001636282-26-000039, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Spyre Therapeutics, Inc. filed document, accession 0001636282-26-000039. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 159,713 | $5,232,198 | — |
| Option | 709,458 | — | $7.50 |
| Option | 150,448 | — | $25.86 |
| Option | 179,209 | — | $10.39 |
| Option | 285,209 | — | $21.66 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Spyre Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
27 Form 4 lines since the FY2025 proxy (filed April 10, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-01 | Sale | 10b5-1 | 4,990 | $93.37 | 537,640 |
| 2026-10-01 | Sale | 10b5-1 | 3,989 | $92.31 | 542,630 |
| 2026-10-01 | Sale | 10b5-1 | 2,683 | $90.10 | 549,257 |
| 2026-10-01 | Sale | 10b5-1 | 2,638 | $91.49 | 546,619 |
| 2026-10-01 | Sale | 10b5-1 | 600 | $89.14 | 551,940 |
| 2026-10-01 | Sale | 10b5-1 | 100 | $93.91 | 537,540 |
| 2026-09-01 | Sale | 10b5-1 | 3,700 | $88.06 | 552,940 |
| 2026-09-01 | Sale | 10b5-1 | 2,500 | $86.36 | 565,040 |
The 8 most recent of 27 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Spyre Therapeutics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $1,030,750 | $20,776,931 | $24,211 | $21,831,892 |
| Change in control and involuntary termination | $1,546,125 | $31,365,923 | $36,317 | $32,948,365 |
| Disability | $0 | $31,365,923 | $0 | $31,365,923 |
| Change in control, no termination | $0 | $5,232,198 | $0 | $5,232,198 |
| Death | $0 | $31,365,923 | $0 | $31,365,923 |
Per the Potential Payments Upon Termination or Change in Control table in Spyre Therapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Spyre Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Cameron Turtle · this page | Chief Executive Officer | $6,707,361 |
| Sheldon Sloan | Chief Medical Officer | $2,211,805 |
| Heidy King-Jones | Chief Legal Officer and Corporate Secretary | $2,192,045 |
| Scott Burrows | Chief Financial Officer | $2,192,045 |
Board service
Spyre Therapeutics board · FY2025How this board is paid
Company policy: Spyre Therapeutics pays directors a $40,000 cash retainer and $350,000 in equity. As stated in Spyre Therapeutics's FY2025 proxy.
The full Spyre Therapeutics compensation record
free company briefThis page is one person within Spyre Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Spyre Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Spyre Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Spyre Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order SYRE
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.